The following symposia are supported by the indicated patrons and are available free to delegates to attend.
Symposia details will be updated as they become available.
Unless indicated in the symposia details below, these sessions are not certified by University of Toronto, the College of Family Physicians of Canada or the Royal College of Physicians and Surgeons of Canada, nor are they under the jurisdiction of the Heart & Stroke Clinical Update.
Friday December 8, 2017
Randomized Control Trials and Real World Evidence: Where do they fit?
Peter Lin, MD CCFP
- Evaluate and understand the differences between randomized clinical trials and real world evidence.
- Understand what information and learnings can be derived from each.
- Review real world evidence examples and how they may apply to practice.
Cardiovascular outcomes trials are becoming a key component of determining the safety and efficacy of type 2 diabetes management therapies. This program is designed to review the clinical trial landscape understanding and evaluating both randomized control trials and real world evidence. You will gain a deeper understanding of how to compare and contrast the different trials as well as review some examples and apply to everyday practice.
This program was supported by educational funding from AstraZeneca Canada Inc.
Choosing the Best Option for Patients: Integrating GLP-1RAs into Type 2 Diabetes Management
Robert Schlosser, MD, FRCPC
Endocrinologist at LMC Endocrinology Centre, Thornhill, Ont.
- Assess the role of GLP-1 receptor agonist (GLP-1RA) therapy in T2DM, focusing on recommendations from Diabetes Canada.
- Compare and contrast the efficacy, safety and dosing of current and upcoming GLP-1RAs.
- Discuss how to integrate the GLP-1RA class into practice, reflecting on specific patient and agent characteristics to optimize T2DM management.
Diabetes Canada recommends that Canadian healthcare providers select a pharmacologic treatment for type 2 diabetes mellitus (T2DM) based on specific patient and agent characteristics, emphasizing individualization. With new and emerging therapies within the GLP-1 receptor agonist (GLP-1RA) class and updates to the guidelines, participants will review the most recently available information and how it can be applied to clinical practice.
Designed by a multidisciplinary committee comprised of family physicians, pharmacists and an endocrinologist, this program highlights common scenarios in which GLP-1RAs may be considered, and provides participants an opportunity to “build” and discuss a patient case.
This program has been certified by the College of Family Physicians of Canada and the Ontario office for up to 1.00 Group Learning credits.
This program was supported by educational funding from Novo Nordisk Canada Inc.
Hot Topics in Atrial Fibrillation
Michael Heffernan, MD PhD FRCPC FACC
Assistant Clinical Professor (adj), McMaster University; Director, Oakville Cardiologists Inc.; Staff Cardiologist, Oakville Trafalgar Memorial Hospital; Director, Heart Function Clinic, Oakville Trafalgar Memorial Hospital
Jeff Habert, MD, CCFP, FCFP
Assistant Professor, Department of Family and Community Medicine, University of Toronto
- Communicate the benefits and risks of anticoagulant therapy to patients with AF
- Describe the similarities and differences among anticoagulants currently available in Canada for stroke prevention in AF
- Recommend appropriate, guideline-recommended anticoagulants at appropriate doses based on patient and drug characteristics
This Group Learning program has been certified by the College of Family Physicians of Canada and the Ontario Chapter for up to 1 Mainpro+ credit.
In compliance with the Innovative Medicines Canada Code of Ethical Practices, this invitation is extended to Healthcare Professionals only.
This program was supported by an unrestricted educational grant from Servier Canada Inc.
If you would like to attend this symposium please email email@example.com with the subject line: Hot Topics in Atrial Fibrillation (Your Name)
Saturday December 9, 2017
Stroke Prevention in AF: Can We Do Better?
Jeffrey Habert MD, FCFP - Chair
Paul Dorian MD, CM, MSc
Jeff Healey MD, FHRS
Part 1: Clinical Conundrums: Personalizing the Management of AF - Real World Worsening Kidney Function
After completing this program, participants will be able to:
- Explain the role of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with chronic kidney disease (CKD);
- Review the clinical challenges presented by patients with worsening kidney function and transitioning from NOACs to warfarin;
- Describe the differences, advantages, and limitations among the formulae used for estimating kidney function; estimated Glomerular Filtration Rate (eGFR) and estimated Creatinine Clearance (eCrCl).
Part 2: Should We Be Mass Screening for AF? Here’s What We Know.
- After completing this program, participants will be able to:
- Consider the benefits of AF screening in high risk populations;
- Describe advantages and limitations of different AF screening tools;
- Implement appropriate strategies to prevent stroke in AF.
The advent of DOACs, as an alternative to warfarin, has revolutionized the management of stroke prevention in atrial fibrillation. As we have gained a better understanding of the management of AF, it may be time to consider the importance of screening for AF in high-risk patient populations, and of applying appropriate treatment strategies to prevent stroke in AF.
This two-part program will encourage you to consider the benefits of AF screening, help you to identify which of your patients should be screened, and provide you with an overview of the advantages and limitations of different screening tools. It will deepen your current understanding of the role of DOACs in the management of stroke prevention and provide guidance on dealing with clinical challenges such as patients with chronic kidney disease and the impact of renal function in the choice of therapy.
There is much more to stroke prevention in AF than meets the eye. This program will challenge your current thinking and provide new tools and knowledge to allow you to better help your patients.
This program was supported by educational funding from Bristol-Myers Squibb and Pfizer Alliance.
Please email firstname.lastname@example.org if you have any questions regarding the industry symposia.